PortfoliosLab logo
NVAX vs. OCGN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NVAX and OCGN is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

NVAX vs. OCGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novavax, Inc. (NVAX) and Ocugen, Inc. (OCGN). The values are adjusted to include any dividend payments, if applicable.

-100.00%-98.00%-96.00%-94.00%-92.00%-90.00%NovemberDecember2025FebruaryMarchApril
-93.48%
-99.90%
NVAX
OCGN

Key characteristics

Sharpe Ratio

NVAX:

0.51

OCGN:

-0.48

Sortino Ratio

NVAX:

2.23

OCGN:

-0.33

Omega Ratio

NVAX:

1.26

OCGN:

0.97

Calmar Ratio

NVAX:

0.75

OCGN:

-0.41

Martin Ratio

NVAX:

1.50

OCGN:

-0.83

Ulcer Index

NVAX:

49.15%

OCGN:

48.87%

Daily Std Dev

NVAX:

143.83%

OCGN:

84.23%

Max Drawdown

NVAX:

-98.82%

OCGN:

-99.97%

Current Drawdown

NVAX:

-97.79%

OCGN:

-99.90%

Fundamentals

Market Cap

NVAX:

$1.20B

OCGN:

$209.37M

EPS

NVAX:

-$1.47

OCGN:

-$0.20

PS Ratio

NVAX:

1.76

OCGN:

51.63

PB Ratio

NVAX:

49.52

OCGN:

6.78

Total Revenue (TTM)

NVAX:

$588.31M

OCGN:

$3.04M

Gross Profit (TTM)

NVAX:

$454.98M

OCGN:

-$5.86M

EBITDA (TTM)

NVAX:

$20.99M

OCGN:

-$40.75M

Returns By Period

In the year-to-date period, NVAX achieves a -12.06% return, which is significantly lower than OCGN's -8.46% return. Over the past 10 years, NVAX has outperformed OCGN with an annualized return of -27.06%, while OCGN has yielded a comparatively lower -48.09% annualized return.


NVAX

YTD

-12.06%

1M

-6.48%

6M

-28.73%

1Y

70.36%

5Y*

-18.69%

10Y*

-27.06%

OCGN

YTD

-8.46%

1M

3.11%

6M

-17.52%

1Y

-37.55%

5Y*

18.89%

10Y*

-48.09%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NVAX vs. OCGN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVAX
The Risk-Adjusted Performance Rank of NVAX is 7979
Overall Rank
The Sharpe Ratio Rank of NVAX is 7272
Sharpe Ratio Rank
The Sortino Ratio Rank of NVAX is 8989
Sortino Ratio Rank
The Omega Ratio Rank of NVAX is 8585
Omega Ratio Rank
The Calmar Ratio Rank of NVAX is 8080
Calmar Ratio Rank
The Martin Ratio Rank of NVAX is 6969
Martin Ratio Rank

OCGN
The Risk-Adjusted Performance Rank of OCGN is 2929
Overall Rank
The Sharpe Ratio Rank of OCGN is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of OCGN is 2828
Sortino Ratio Rank
The Omega Ratio Rank of OCGN is 3030
Omega Ratio Rank
The Calmar Ratio Rank of OCGN is 2626
Calmar Ratio Rank
The Martin Ratio Rank of OCGN is 3434
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NVAX vs. OCGN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and Ocugen, Inc. (OCGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for NVAX, currently valued at 0.51, compared to the broader market-2.00-1.000.001.002.003.00
NVAX: 0.51
OCGN: -0.48
The chart of Sortino ratio for NVAX, currently valued at 2.23, compared to the broader market-6.00-4.00-2.000.002.004.00
NVAX: 2.23
OCGN: -0.33
The chart of Omega ratio for NVAX, currently valued at 1.26, compared to the broader market0.501.001.502.00
NVAX: 1.26
OCGN: 0.97
The chart of Calmar ratio for NVAX, currently valued at 0.75, compared to the broader market0.001.002.003.004.005.00
NVAX: 0.75
OCGN: -0.41
The chart of Martin ratio for NVAX, currently valued at 1.50, compared to the broader market-10.00-5.000.005.0010.0015.0020.00
NVAX: 1.50
OCGN: -0.83

The current NVAX Sharpe Ratio is 0.51, which is higher than the OCGN Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of NVAX and OCGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
0.51
-0.48
NVAX
OCGN

Dividends

NVAX vs. OCGN - Dividend Comparison

Neither NVAX nor OCGN has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NVAX vs. OCGN - Drawdown Comparison

The maximum NVAX drawdown since its inception was -98.82%, roughly equal to the maximum OCGN drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for NVAX and OCGN. For additional features, visit the drawdowns tool.


-100.00%-99.50%-99.00%-98.50%-98.00%-97.50%-97.00%-96.50%NovemberDecember2025FebruaryMarchApril
-97.79%
-99.90%
NVAX
OCGN

Volatility

NVAX vs. OCGN - Volatility Comparison

Novavax, Inc. (NVAX) has a higher volatility of 38.02% compared to Ocugen, Inc. (OCGN) at 32.55%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than OCGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%40.00%NovemberDecember2025FebruaryMarchApril
38.02%
32.55%
NVAX
OCGN

Financials

NVAX vs. OCGN - Financials Comparison

This section allows you to compare key financial metrics between Novavax, Inc. and Ocugen, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items